Literature DB >> 21136672

Proteomics analysis of cellular components in lentiviral vector production using Gel-LC-MS/MS.

Jun X Wheeler1, Christopher Jones, Robin Thorpe, Yuan Zhao.   

Abstract

Among the gene therapy vectors developed to date, lentiviral vectors persist in the host and are therefore best suited for long-term gene transfer and gene-replacement therapies. Human immunodeficiency virus (HIV)-1-based lentiviral vector products are currently produced by transient transfection, filtration and ultracentrifugation, and the quality of the resultant vector product is variable. We reason that by identifying host proteins co-produced with viral vectors we may better understand the mechanism of viral vector production, and improve the safety and quality of the resultant products. Our LC-MS/MS studies identified both viral vector proteins and host proteins, including nuclear proteins, elongation factors and chaperone and heat shock proteins (HSP), and confirmed the presence of known HIV-incorporated proteins, e.g. elongation factor-1α, HSP70 and Histone 2A, demonstrating the capability and viability of LC-MS/MS methods for the proteomic analysis of highly complex samples. Evaluation of the functions of the identified components is in progress to understand their implication for product quality and safety. These studies support the development of improved production and characterisation methods and advance the clinical application of lentiviral vector-based products.
Copyright © 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Year:  2007        PMID: 21136672     DOI: 10.1002/prca.200600522

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  3 in total

1.  Mass spectrometry analysis reveals differences in the host cell protein species found in pseudotyped lentiviral vectors.

Authors:  Sabine Johnson; Jun X Wheeler; Robin Thorpe; Mary Collins; Yasuhiro Takeuchi; Yuan Zhao
Journal:  Biologicals       Date:  2018-02-01       Impact factor: 1.856

2.  Dosing and Re-Administration of Lentiviral Vector for In Vivo Gene Therapy in Rhesus Monkeys and ADA-Deficient Mice.

Authors:  Denise A Carbonaro-Sarracino; Alice F Tarantal; C Chang I Lee; Michael L Kaufman; Stephen Wandro; Xiangyang Jin; Michele Martinez; Danielle N Clark; Krista Chun; Colin Koziol; Cinnamon L Hardee; Xiaoyan Wang; Donald B Kohn
Journal:  Mol Ther Methods Clin Dev       Date:  2019-11-16       Impact factor: 6.698

3.  Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins.

Authors:  Samagya Banskota; Aditya Raguram; Susie Suh; Samuel W Du; Jessie R Davis; Elliot H Choi; Xiao Wang; Sarah C Nielsen; Gregory A Newby; Peyton B Randolph; Mark J Osborn; Kiran Musunuru; Krzysztof Palczewski; David R Liu
Journal:  Cell       Date:  2022-01-11       Impact factor: 66.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.